European Leukemia Trial Registry
Trial: CLBH589H2101

More Details
Title Phase Ib study of Panobinostat and 5-Azacitidine for MDS, CMML or AML
Scientific Title A Phase I/b, open-label, multi-center, dose-escalation study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) or acute myeloid leukaemia (AML)
Short Title CLBH589H2101
Trialgroup NN
Type of Trial multicentric, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.10.2009
Leader Ottmann, Prof. Dr., Oliver
Contactperson

principal investigator
Ottmann, Prof. Dr., Oliver
Tel: +49 (0)69 6301 87070
Fax: +49 (0)69 6301 4170
Email: ottmann@em.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
created 17.11.2009 Irene Gleske
changed 01.06.2015 Hanna Ebert
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org